drugset / Trial / NCT00234429

A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

NCT00234429

Phase 2/3 Completed 74 enrolled AstraZeneca
RandomizedSingle-groupDouble-blindTreatment

Summary

The primary objective of this study is to compare the activity of raltitrexed and ZD1839 versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by estimating progression free survival (PFS) in each treatment arm.

Timeline

Start
2003-11
Primary completion
Completion
2006-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule
Subject Raltitrexed Small molecule

Indications